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Mitochondria-Centric Activation Induced Cell Death of Cytolytic
T Lymphocytes and its Implications for Cancer Immunotherapy
Arvind Chhabra
Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA.
Abstract
Premature death of the adoptively transferred cytolytic T lymphocytes (CTL) by means of
activation induced cell death (AICD) represents one of the major constraints in devising an
effective anti-cancer immune intervention strategy. Understanding the mechanism of AICD is,
therefore, critical for developing methods to interfere with this death process. Although the
existing paradigm on AICD centers around the initiation of the cascade of events originating from
the engagement of death receptors leading to the activation of effector caspases and eventually
resulting in cell death, recent findings have questioned the universal role of caspases as the cell
death executioners. We here review our current understanding of the contribution of caspase-
dependent and caspase-independent death executioners in AICD of T cells. We will also discuss
the involvement of mitochondria-centric death pathway in AICD of human tumor associated
antigen specific primary CTL and its implications in cancer immunotherapy.
Keywords
Cancer; Immunotherapy; Melanoma
Introduction
Since the identification of first human tumor associated antigenic epitope in melanoma
model [1], a substantial progress has been made towards understanding the molecular and
cellular basis of the generation of a productive anti-tumor immune response. Numerous
cancer-associated antigens have been in different human tumor models, CD8+ tumor antigen
specific T cells have been recognized as the key facilitators of the adaptive antitumor
immune response and the molecular signals that modulate T-cell activation, effector
function and memory generation have also been characterized in greater details. Since most
human tumors are MHC class I positive but MHC class II negative [2–4], i.e. CD8+ T cells
can target them but CD4+ T cells cannot, a great majority of the current cancer
immunotherapy strategies are aimed at activation and expansion of tumor antigen specific
CD8+ cytolytic T lymphocyte (CTL) precursors.
Interestingly, most current immunotherapy approaches can be put into two broad categories,
active specific immunization and adoptive immunotherapy. Of these, active immunization
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involves the administration of DC based vaccine regimens, while adoptive immunotherapy
involves the administration of patient specific ex-vivo expanded anti-tumor cytolytic
immune effectors. Although both these approaches have been shown to produce a
productive clinical response, a greater degree of success has been achieved with adoptively
transferred tumor antigen specific killer T cells than with the active immunization based
approaches [3]. One possible explanation for this could be the fact that the vaccine regimens
administered in active immunization based approaches have to overcome multiple redundant
regulatory mechanisms of the host immune system to facilitate the generation of an effective
anti-tumor CTL response, while the quality of the anti-tumor immune effectors to be
administered under adoptive immunotherapy could be better controlled. However, it is now
well-established that the mere presence of the anti-tumor T cell in cancer patients, generated
in-vivo through active specific immunization based approaches or adoptively administered
ex-vivo expanded CTL, does not always guarantee an objective clinical response [3,5].
Therefore, a critical analysis of different mechanisms hindering the success of immune
based cancer therapy approaches is required to develop potent strategies to effectively target
the growing tumor.
Among the possible reasons for the low success rate with CTL based immunotherapy
includes the premature elimination of anti-tumor CTL by means of epitope specific AICD
upon encountering their target antigen on tumor cells [6]. Although this concept has been
extensively looked at under the ``tumor counter attack`` hypothesis [7,8], however, these
studies envisioned Fas-Fas ligand engagement as the sole mechanism of the deletion of
tumor antigen specific CTL. Interestingly, recent findings from different laboratories,
including ours, have questioned the universal role of death receptors as the key initiators and
caspases as the sole executioners of cell death in T cells in general, and in human tumor
antigen specific primary CTL in particular [9–13]. It has been shown that the death of
human tumor antigen specific T cells upon exposure to their cognate antigens, is an intrinsic
caspase-independent process [9,10]. We here try to reconcile the recent findings with the
existing paradigm on T cell death and update our understanding of the mechanism of AICD
in human tumor antigen specific primary T cells. Table-1 summarizes the key advances in T
cell based cancer immunotherapy field and the obstacles limiting the success of current
immunotherapy approaches.
Contribution of caspase-dependent and caspase-independent cell death
pathways in AICD of T cells
Figure. 1 schematically shows the kinetics of an antigen specific T cell response. As shown,
T cells expand enormously upon recognition of their cognate antigenic epitope in context
with the professional antigen presenting cells (APC). However, mechanisms such as
programmed cell death (PCD) and AICD ensure that the excess antigen specific T cells are
cleared off, once the antigen load has subsided, to maintain the immune homeostasis. As a
result, a great majority of antigen specific effector T cells die through these mechanisms,
leaving behind a very small population of memory T cells. Although PCD and AICD are
essential host immune homeostasis mechanisms, a premature elimination of adoptively
administered or in-vivo generated tumor antigen specific T cells through epitope specific
AICD could limit the efficacy of T cell based cancer immunotherapy strategies. Therefore, it
is a reasonable expectation that by interfering with the AICD process, the clinical efficacy of
anti-tumor T cells could be significantly improved.
Interestingly, the seminal studies on AICD in T cells were done in T cell hybridomas, Jurkat
cells, T cell lines and TCR and/ or super antigen-driven T cells [14,15]. These studies were
followed by studies in lpr and gld mice lacking Fas and FasL respectively, that showed
excess lymphocytes and highlighted the critical requirement of death receptors (DR)-
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mediated signals in leukocyte survival [16,17]. Death-receptors (e.g. Fas, TNF-R1 etc.) are
surface expressed receptors that contain a conserved domain called death domain (DD) on
their cytoplasmic domains that transmits the signal received from the extra-cellular milieu.
The engagement of the death receptors with their ligands leads to the recruitment of adaptor
proteins, Fas-associated death domain (FADD) and TNF-receptor 1-associated death domain
(TRADD), via interactions between their death domains and formation of a death-inducing
signaling complex (DISC) [18,19]. Through homotypic interaction of death effector domain
(DED), FADD causes the recruitment and activation of caspase-8 followed by the activation
of effector caspase, caspase-3, leading to the DNA degradation and ultimately cell death
[18,19].
All these studies led to the current paradigm on AICD of T cells that states that the initiation
of cascade of events originating from the engagement of death receptors leads to the
activation of effector caspases and culminates in cell death. However, recent reports have
not only questioned the indispensability of death receptors and caspases in T cell death
[12,20–22], caspases have also been shown to play key role in cell proliferation [23–25]. T
cells from lpr and gld mouse have also been shown to undergo caspase-independent death
[26], and Fas has also been shown to play critical role in caspase-mediated cell death via
recruitment of FADD and caspase-8 and caspase-10 followed by activation of caspase-3; it
has also been implicated in execution of the caspase-independent cell death via recruitment
of RIP molecule, under some conditions [19,27,28]. The over expression of caspase-
inhibitor FLIP in mouse has also been shown to increase the resistance of their T cells to Fas
mediated death, but it did not result in the increased accumulation of T cells. Furthermore,
mice lacking caspases-1, 2, 3, 6, 9, 11, and 12 have all been shown to possess a
hematopoietic system of normal size and composition, while caspase-8−/− embryos have
been shown to possess abnormally low numbers of blood cells (reviewed in [29]). Although
these results could be explained by a possible redundancy in the use of these caspases in the
developmentally programmed death of leukocytes, however, alternatively, it could also
mean that the caspases are not the sole determinants of survival of immune cells in
physiology.
Taken together, these reports strongly recommend a careful re-examination of the
contribution of caspase-independent death pathways in T cell survival and maintenance of
immune homeostasis. This is especially important with respect to the human antigen specific
primary T cells, since seminal studies on AICD in T lymphocytes were carried out with
transformed cell lines and with the addition of cytokines/ drugs [14,15,30,31]. These
findings could not be confirmed at that time in antigen specific human primary T cells, due
to the unavailability of the methods to generate sufficiently large numbers of antigen
specific T cells for systematic biochemical analyses, and also due to the unavailability of the
technologies and tools to characterize human antigen specific primary T cells. Even after the
availability of such tools and methodologies not enough emphasis was put on such studies
since this was not considered to be or immense importance, however, with the realization
that the AICD might be a key limiting factor hindering the success of current T cell based
cancer-immunotherapy approaches, these studies becomes very important. Furthermore,
with recent reports suggesting the existence of a caspase-independent death pathway in
regulation of T cell survival and maintenance of immune homeostasis, especially in
regulation of epitope specific AICD in human tumor antigen specific T cells [9–13], these
studies become even more critical. A clear understanding of the mechanism of AICD in
human tumor reactive CTL will allow us to interfere with this process and improve the
efficacy of the T cell based cancer-immunotherapy protocols. Table-2 summarizes the key
developments that have led to the current understanding of the T cell death, in general, and
AICD in human anti-tumor T cells, in particular.
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Involvement of Mitochondria-Centric Death Pathway in AICD
Mitochondria has received much attention for its role in regulation of the cell death process
in various systems including human primary CTL, since it harbors many apoptotic death
executioners, that are involved in caspase-dependent as well as caspase-independent cell
death pathways [10,32–34]. Both extrinsic (DR-mediated) as well as intrinsic pathways of
cell death converge upon mitochondria and mitochondria plays a crucial role in execution of
cell death by caspase-dependent pathway as well as by caspase-independent pathways
[32,34,35]. The most well studied apoptotic factor released from the permeabilized
mitochondria is the respiratory component cytochrome-c [32]. Upon release into the
cytoplasm, cytochrome-c activates Apaf-1 and triggers the caspase cascade leading to the
activation of executioner caspase, caspase-3 [32]. Activated caspase-3 then cleaves the
inhibitor of caspase-activated DNase (ICAD), which allows caspase-activated DNase (CAD)
to enter the nucleus and lead to the oligonucleosomal DNA fragmentation [36,37]. More
recently, mitochondrial membrane permeabilization in response to apoptotic signals has
been shown to release the proapoptotic factors, such as Smac/ Diablo and HtrA2/ Omi [38–
40]. These proteins facilitate the caspase activation by binding to and inhibiting the function
of members of the inhibitor of apoptosis protein (IAP) family [41,42]. Interestingly, HtrA2/
Omi also possess a serine protease activity, which contributes to the caspase-independent
cell death processes [40].
Mitochondria also harbor death inducers such as apoptosis-inducing factor (AIF) and
Endonuclease G (EndoG), that mediate cell death in caspase-independent manner [43,44]. In
healthy cells, AIF is retained in the mitochondria where it performs an oxidoreductase
function based on the presence of a FAD binding domain in the N-terminus and its redox
activity [45].
However, similar to the bifunctional role of cytochrome-c, when AIF is released from the
mitochondria in response to the apoptotic stimuli it becomes an active executioner of the cell
death. Following an apoptotic stimulus, AIF translocates to the nucleus and trigger the
chromatin condensation in a caspase-independent manner [11,13,43,46,47]. Although it was
earlier believed that a breach in mitochondrial permeability results in complete breakdown
of mitochondrial integrity resulting in the release of mitochondria resident apoptosis
inducing proteins, recent findings have shown that this is a highly regulated process, and the
mitochondrial death effector proteins can also be selectively released without any
concomitant release of cytochrome-c [48–50].
Interestingly, the contribution of caspase-independent mitochondria-centric death pathway
in AICD of human primary T lymphocytes has not yet been systematically examined.
Towards this, our recent work on AICD in human melanoma model suggesting the existence
of a tightly regulated mitochondria-centric death pathway in regulating the AICD of human
tumor antigen specific primary CTL [10], is quite encouraging. We have found that the
AICD of human melanoma-associated antigenic epitope, MART-127–37, specific primary
CTL is associated with the selective release of mitochondrial death effector protein, AIF
[10], and that this death is a JNK activation driven, caspase-independent, DR-independent
process. Figure. 2 schematically summarize our current understanding of the caspase-
dependent and caspase-independent pathways of cell death in T cells (Fig.2).
Regulation of Mitochondrial Permeability During AICD Process
Mitochondria are surrounded by a double membrane, which divides them into two sub-
compartments. A transmembrane channel, called the permeability transition pore or PTP, is
formed at the contact sites between the inner (IMM) and outer mitochondrial membrane
(OMM). The core components of PTP are the voltage-dependent anion channel (VDAC) in
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the OMM and the adenine nucleotide translocator (ANT) in the IMM. VDAC makes the
OMM permeable to most small molecules (<5 kDa), allowing free exchange of respiratory
chain substrates [51,52]. Breach in mitochondrial permeability is the key event during
mitochondrial cell death pathway, resulting in release of apoptotic proteins, such as
cytochrome-c, AIF, Endo-G etc.
The Bcl-2 family pro- and anti-apoptotic proteins function as “arbiters” of mitochondrial
membrane integrity [53]. Bcl-2/Bcl-XL, the prototypic anti-apoptotic proteins maintain
mitochondrial membrane integrity and function as anti-apoptotic proteins by regulating the
mitochondrial permeability transition pore complex (PTPC) [54,55]. Bak and Bax, the
prototypic pro-apoptotic Bcl-2 family members affect the mitochondrial outer membrane
potential (MOMP) by regulating the VDAC activity of the mitochondrial permeability
transition pore [54,55] while the pro-apoptotic BH3-only members such as Bid and Bim
appear to induce oligomerization of Bax and Bak resulting in the release of mitochondrial
apoptogenic factors [55,56]. P53 has also been recently shown to influence the integrity of
the mitochondria, in a post-translational manner, by interacting with the Bcl family proteins
[57,58]. Studies in mouse models have clearly established that the Bcl-family proteins play a
critical role in the survival of T lymphocytes [53,59,60]. Similar to the studies in lpr and gld
mouse models [16,17], abnormalities in the Bcl-2-regulated signaling pathways, such as the
expression of a bcl-2 transgene, loss of BH3-only protein Bim, or a combined deletion of
Bax and Bak, have all been shown to cause extensive lymphoid and myeloid cell
accumulation [reviewed in [61]]. However, the distinct nature of the death receptor-induced
and Bcl-2-regulated pathways of apoptosis is highlighted by the observations that the
expression of bcl-2 transgene in lpr or gld mice enhances lymphadenopathy [62,63].
Interestingly, while over-expression or loss of Bcl-2 family members can lead to hyperplasia
or hypoplasia of hematopoietic cell populations, to date none of the knockout mutations of
any of the caspases have had such dramatic effects in the hematopoietic system. Since Bcl-
family proteins play a critical role in the T cell survival and they function as key regulators
of the mitochondrial membrane integrity, it is critical to systematically examine their role in
the regulation of mitochondria-centric pathway in AICD of human tumor antigen specific
primary T cells.
Involvement of JNK in Regulation of Mitochondira-Centric AICD of T Cells
The c-Jun N-terminal kinases were first identified in 1990 as the cycloheximide activated
protein kinases in rodent liver [64]. Soon after, it was found that the JNK kinases are
activated in response to a wide array of stress conditions, and it is now well-established that
JNK plays a critical role in stress induced apoptosis [65], neuronal cell apoptosis [66] and
also in the central deletion of T cells [67–69]. JNK is known to have ten isoforms that are
encoded by alternative splicing of three genes, JNK1, JNK2 and JNK3 [70]. JNK is
activated by dual phosphorylation in response to a variety of apoptotic stimuli, for example,
osmotic stress, redox stress, growth factor withdrawal, radiation etc., and the Bcl-2 family
proteins have been shown to play key role in JNK mediated cell death pathways
[48,56,66,69,71,72]. Bim has been shown to relay the apoptotic signal originating from JNK
activation to the mitochondria and leads to release of apoptotic proteins [66,73]. JNK-
mediated phosphorylation of Bim results in Bax dependent apoptosis [73]. In addition, Bim
has also been shown to participate in cell death process in a VDAC-dependent manner [74].
Bax and Bak are critical players in the JNK-dependent cell death pathway [65,75].
Interestingly, we have found that the JNK activation is also a critical event in DR-
independent, caspase-independent, mitochondria-centric AICD of human melanoma
associated antigenic epitope, MART-127–35 specific primary CTL [9,10]. AICD in these
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cells is associated with a selective release of AIF without any concomitant cytochrome-c
release that culminates in cell death mediated by a large- scale DNA fragmentation [9,10];
and blocking JNK activation prevents the mitochondrio-nuclear translocation of AIF, large-
scale DNA fragmentation and rescues these CTL from undergoing AICD [9]. Bim and
Mcl-1 play significant role in this JNK activation driven AICD process ([9], and
unpublished observations). Bim is upregulated in CTL undergoing AICD [9,76], and
blocking JNK activation results in upregulation of Mcl-1 and prevention of AICD [9]. Taken
together, these findings suggest that the JNK activation coupled with the Bcl-family proteins
involvement modulates the mitochondrial membrane integrity in human tumor antigen
specific primary CTL and controls the fate of these cells during the epitope specific AICD
process.
It should also be mentioned here that JNK also plays a crucial role in the generation of T cell
effector function, for example IFN-γ production [9,77]. Therefore, it is critical to carefully
define, how does activated JNK participate in the effector phase (IFN-γ secretion) as well as
in AICD process. Among the possibilities, the transient versus sustained JNK activation
have been shown to exhibit a differential effect on cell death [78]. A similar mechanism can
also be envisioned in this case and AICD in the primary CTL could result from a sustained
JNK activation. It is also possible that the AICD in these cells result from the activation of
the mitochondria-resident JNK, a possibility that has been proposed in JNK-driven apoptosis
of other cell types [66,67]. Furthermore, it is also quite possible that the different isotypes of
JNK are involved in the regulation of the effector function and the cell death pathways of
antigen specific T cells.
Future studies should provide key insights on the mechanism of JNK activation driven
AICD process in human tumor antigen specific T cells. Studies in tumor antigen specific
CTL in cancer models other than melanoma and in tumor antigen specific T cells other than
MART-1, and also in customized anti-tumor CTL generated through TCR engineering based
approaches [79–81], are also needed to establish the generality of these findings. In addition,
systematic studies are also needed in pre-clinical animal models to test the in-vivo
superiority of AICD resistant antitumor CTL to target a growing tumor over natural CTL.
The in-vivo efficacy of pharmacological inhibitor based and RNAi based approaches also
need to be critically examined. Such studies are crucial since AICD mediators such as JNK
can also have critical physiological role (IFN-γ) and knocking them down could have
undesired consequences. Towards this, the availability of the clinical grade pharmacological
inhibitors of JNK (reviewed in [82]) should make it feasible to address these issues in a
straightforward manner. The outcome of these studies will be crucial to advance these
laboratory findings into the clinic.
Conclusion
Since it conception, the tumor immunology field has made a great deal of progress and it has
been clearly shown that, despite most tumor antigens being “self-antigens”, it is indeed
possible to generate productive anti-tumor tumor immune responses of dramatic clinical
precision and efficacy. This is especially significant given the fact that even the most
successful infectious disease vaccines have not been shown to be as effective against a
progressive disease, as the immune based therapies targeting a progressing metastatic tumor.
However, despite a great deal of progress having been made towards the identification of a
range of tumor antigens, and towards the development of several novel strategies to target a
growing tumor, the success with the current immune based cancer therapies has not yet met
the expectations.
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Tumor immunologists have come to an agreement that the mere generation of an anti-tumor
immune response is not going guarantee success, since the tumor microenvironment is quite
a complex entity and a growing tumor employs multiple immune escape strategies to avoid/
counter the host immune surveillance mechanisms. For instance, tumors can down regulate
antigen processing and presentation machinery (e.g., MHC molecules). Tumors can secrete
inhibitory cytokines, such as IL-10 and transforming growth factor (TGF)-β, that can inhibit
the dendritic-cell maturation, lead to the dysfunction of tumor infiltrating immune effectors
and also could facilitate the recruitment of regulatory T cells (Treg). Many tumors express
ligands that can interact with the infiltrating T cells to provide a negative stimulation, which
inhibits or reduces the effector functions of tumor specific cytotoxic T lymphocytes. In
addition, elimination of anti-tumor immune effectors by means of AICD is another factor
hindering the success of the T cell based cancer immunotherapy approaches. Therefore, a
successful immune based cancer therapy will not only have to guarantee the generation of a
robust anti-tumor immune response, it will also have to ensure that the immune effectors
generated are well equipped to counter/ overcome the immunosuppressive tumor
microenvironment.
Towards this, the tumor reactive CTL that are less susceptible to undergo a premature
AICD-mediated elimination sounds a reasonable strategy. Understandably though, a clear
understanding of the TCR triggered cascade of events leading to the epitope specific AICD
in human primary CTL is critical to interfere with the premature death of these tumor
specific cytolytic T cells. In addition, with a considerable progress being made towards
generating customized anti-tumor T cells through the TCR engineering based approaches,
and also towards utilizing stem cells to generate patient specific T cells, a thorough
understanding of the biology of human tumor antigen specific T cells will be very helpful in
creating the next generation of anti-tumor immune effectors.
Finally, we would like to end our discussion by pointing out that with so many exciting
happenings, the future of tumor immunology field could not have looked any more
promising. It will be very interesting to see how soon all these advances can actually help
the immune based cancer therapy to meet its clinical expectations.
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Figure 1. Kinetics of an antigen specific T cell response
As shown an antigen specific T cell response in comprised of three distinct phases:
expansion, contraction, and memory.
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Figure 2. Extrinsic and Intrinsic T cell death pathways
(Left Panel). The existing paradigm (left panel) states that the T cell death is triggered by
the engagement of the surface expressed death receptors (DR) with their corresponding
death ligands that leads to the activation of caspases and results in oligosomal DNA
degradation mediated cell death. (Right Panel). Recent report suggest that the T cell death,
especially the epitope specific activation induced cell death (AICD) in human tumor antigen
specific T cells (right panel) is an intrinsic, DR-independent, mitochondria-centric process,
in which JNK and mitochondria-resident death executioner, apoptosis inducing factor (AIF)
play crucial roles [9,10].
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Table-1
T Cell Based Cancer Immunotherapy: Key Developments And Current Constraints.
Key Developments:
• Identification of the first human tumor associated antigen [1].
• Isolation of human tumor associated antigen specific T cell clones [83–85].
• Development of methodologies for a large-scale generation of dendritic cells, in vitro [86,87].
• Development of active specific immunization based cancer immunotherapy strategies [88–90].
• Development of adoptive administration based cancer immunotherapy strategies [91–93].
• Development of TCR engineering based cancer immunotherapy approaches [79–81,94].
Current Constraints:
• Regulatory T cell mediated immune suppression.
• Immunosuppressive tumor microenvironment and immune dysfunction mechanisms.
• Activation induced cell death (AICD) mediated elimination of anti-tumor T cells, generated in-vivo or ex-vivo expanded
administered CTL.
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Table-2
AICD In T Cells: Death Receptor (DR)-Driven, Caspase Executed Vs Caspase-Independent Pathways.
• Development of the DR-initiated, caspase-executed paradigm on T cell death [14,15,30,31], and the tumor counterattack hypothesis
[95].
• Caspase-independent death in T cell [11,96].
• Involvement of mitochondria in cell death pathways [32–34].
• Recent studies supporting the existence of a DR-independent, caspase-independent, mitochondria-centric death pathway in AICD of
human anti-tumor T cells [9,10].
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